Clinical Trial Update: Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating iberdomide versus observation off therapy after idecabtagene vicleucel CAR-T therapy in adults with multiple myeloma. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Abecma (idecabtagene vicleucel)
• iberdomide (iberdomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING